These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8731007)

  • 1. The impact of patient compliance on drug concentration profile in multiple doses.
    Wang W; Husan F; Chow SC
    Stat Med; 1996 Mar; 15(6):659-69. PubMed ID: 8731007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies.
    Vrijens B; Goetghebeur E
    Stat Med; 2004 Feb; 23(4):531-44. PubMed ID: 14755387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout.
    de Klerk E; van der Heijde D; Landewé R; van der Tempel H; Urquhart J; van der Linden S
    J Rheumatol; 2003 Jan; 30(1):44-54. PubMed ID: 12508389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug therapy reviews: clinical pharmacology of antiepileptic drugs.
    Browne TR
    Am J Hosp Pharm; 1978 Sep; 35(9):1048-56. PubMed ID: 358830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models.
    Vrijens B; Tousset E; Rode R; Bertz R; Mayer S; Urquhart J
    J Clin Pharmacol; 2005 Apr; 45(4):461-7. PubMed ID: 15778427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient adherence to prescribed antimicrobial drug dosing regimens.
    Vrijens B; Urquhart J
    J Antimicrob Chemother; 2005 May; 55(5):616-27. PubMed ID: 15772145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monitoring of therapy using drug concentration levels: Why? When? How?].
    Vozeh S
    Ther Umsch; 1990 Aug; 47(8):635-9. PubMed ID: 2218964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cross-national comparison of drug compliance and non-compliance associated factors in the elderly with polypharmacotherapy].
    Topinková E; Fialová D; Carpenter GI; Bernabei R
    Cas Lek Cesk; 2006; 145(9):726-32. PubMed ID: 17091729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
    DeVane CL; Gill HS
    J Clin Psychiatry; 1997; 58 Suppl 5():7-14. PubMed ID: 9184622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady-state clearance rates of warfarin and its enantiomers in therapeutically dosed patients.
    McAleer SD; Foondun AS; Feely M; Chrystyn H
    Chirality; 1997; 9(1):13-6. PubMed ID: 9094197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The repeated one-point method for predicting dose sizes with irregular dosing intervals.
    Thompson GA; Ritschel WA
    Int J Clin Pharmacol Ther Toxicol; 1986 Jul; 24(7):337-43. PubMed ID: 3733283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (innopran XL) , a new chronotherapeutic formulation.
    Sica D; Frishman WH; Manowitz N
    Heart Dis; 2003; 5(3):176-81. PubMed ID: 12783630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability and singularity arising from poor compliance in a pharmacokinetic model II: the multi-oral case.
    Fermín LJ; Lévy-Véhel J
    J Math Biol; 2017 Mar; 74(4):809-841. PubMed ID: 27431876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoid metabolism and transplacental pharmacokinetics in the cynomolgus monkey following a nonteratogenic dosing regimen with all-trans-retinoic acid.
    Tzimas G; Nau H; Hendrickx AG; Peterson PE; Hummler H
    Teratology; 1996 Nov; 54(5):255-65. PubMed ID: 9035347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes).
    Kardas P
    Diabetes Obes Metab; 2005 Nov; 7(6):722-8. PubMed ID: 16219016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
    Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK
    Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.